Fundz

Evolus

Newport Beach · Fitness, Healthcare, Health Care · 400 employees

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technol

Funding history

  • Series revolving credit facility — $30.0M — Mar 2026
  • Funding Round — $125.0M — Dec 2021
  • Funding Round — $40.0M — Jul 2020

Recent signals

  • Mar 13, 2026: Evolus Appoints Vikram Malik as Class II Director
  • Mar 13, 2026: SEC 8-K (5.02): On March 13, 2026, Evolus, Inc. announced the reclassification of Vikram Malik from Class III to Class II of its board of directors following the resignation of Simone Blank. This reclassification was necessary to maintain balance among the director classes after Ms. Blank stepped down to support board refreshment efforts. Mr. Malik's transition involved his immediate resignation as a Class III director, followed by his appointment as a Class II director. This strategic move is aimed at enhancing the diversity and effectiveness of the board's governance structure.
  • Mar 03, 2026: Raised $30.0M in Series revolving credit facility
  • Mar 03, 2026: SEC 8-K (1.01): On March 3, 2026, Evolus, Inc. entered into a Loan and Security Agreement with Eclipse Business Capital LLC. This agreement establishes a senior secured asset-based revolving credit facility amounting to up to $30 million, with an additional uncommitted accordion feature of $10 million. The facility is based on eligible accounts receivable and inventory, with a minimum utilization requirement of $10 million. The Loan Agreement matures on March 3, 2029, and includes terms for interest rates linked to standard adjustments.
  • Mar 03, 2026: SEC 8-K (1.01): On March 3, 2026, Evolus, Inc. entered into a Loan and Security Agreement with Eclipse Business Capital LLC and associated lenders, establishing a senior secured asset-based revolving credit facility valued at up to $30.0 million. This facility is contingent upon a borrowing base formula summarizing eligible accounts receivable and inventory, with customary reserves applied. Notably, the agreement includes an additional accordion feature allowing for up to $10.0 million subject to lender consent, and it features a minimum utilization requirement of $10.0 million. The facility matures on March 3, 2029, indicating a significant financial step for Evolus towards enhancing operational capital and flexibility.
  • Sep 08, 2025: Evolus Appoints Tatjana Mitchell as Chief Financial Officer
  • Feb 13, 2025: Launched Evolus, Inc. announces FDA approval of Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid gels aimed at enhancing their aesthetic portfolio.
  • Oct 31, 2024: Launched Evolus, Inc. Announces EU Certification of Estyme® Injectable Gels for Enhanced Aesthetic Treatments.

See plans & pricing → Track Evolus’s funding, hiring, and signals — with verified contacts — on Fundz.